Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines for cancer based on the principle of synthetic lethality. The company operates within the biopharmaceutical and oncology drug development industry, with a core emphasis on genetically defined cancers that are underserved by existing therapies. Tango Therapeutics’ approach is rooted in leveraging large-scale functional genomics and computational biology to identify cancer-specific vulnerabilities.
The company’s primary business involves the research and development of small-molecule cancer therapeutics, with its leading programs targeting tumors with specific genetic alterations such as MTAP deletions. Tango Therapeutics was founded in 2016 by academic scientists affiliated with the Broad Institute and Harvard Medical School, including Leif Ellisen, and was established to translate academic discoveries in cancer genetics into targeted therapies. The company completed an initial public offering in 2021 and is listed on the Nasdaq under the ticker TNGX.
Business Operations
Tango Therapeutics operates as a single-reportable segment focused on oncology research and drug development. The company generates no product revenue and is primarily funded through public equity, private capital, and strategic collaborations. Its operations center on preclinical research, clinical development, and early-stage clinical trials for its pipeline candidates, with lead programs including PRMT5 inhibitors and other synthetic lethal targets.
The company conducts the majority of its research and development activities internally, supported by proprietary discovery platforms and licensed intellectual property. Tango Therapeutics has entered into strategic research and development collaborations, most notably with Gilead Sciences, which provides research funding and milestone-based payments. The company does not currently report any material operating subsidiaries, and manufacturing and certain development activities are outsourced to third-party providers.
Strategic Position & Investments
Strategically, Tango Therapeutics is focused on advancing a pipeline of targeted oncology therapies for biomarker-defined patient populations, with an emphasis on first-in-class or best-in-class potential. Its growth strategy centers on progressing internal discovery programs into clinical development while selectively partnering assets to share risk and capital requirements. The company continues to invest heavily in its discovery engine to expand its pipeline beyond its lead programs.
Tango Therapeutics’ most significant investment activity has been internal, directed toward clinical trials, platform development, and intellectual property expansion. The collaboration with Gilead Sciences represents a key strategic partnership supporting both validation of its science and non-dilutive capital. Beyond this collaboration, no material acquisitions or equity investments in external portfolio companies have been publicly disclosed.
Geographic Footprint
Tango Therapeutics is headquartered in Cambridge, Massachusetts, a major global hub for biotechnology and life sciences. Its operations are primarily based in the United States, where it conducts research, development, and corporate activities. The company’s clinical trials include sites within the U.S. and, where applicable, internationally through contracted research organizations.
While Tango Therapeutics does not maintain significant physical operations outside the United States, its development programs and collaborations give it an indirect international presence, particularly through global clinical trial enrollment and partnerships with multinational pharmaceutical companies.
Leadership & Governance
Tango Therapeutics is led by an executive team with experience in oncology drug development, biotechnology operations, and pharmaceutical finance. The leadership emphasizes a strategy grounded in rigorous science, disciplined capital allocation, and a focus on genetically defined patient populations.
Key executives include:
- Barbara Weber, M.D. – Chief Executive Officer
- Mahesh Karande – Chief Financial Officer
- Brandon Moyer, Ph.D. – Chief Scientific Officer (data inconclusive based on available public sources)
The company is governed by a board of directors composed of industry executives, scientific leaders, and investor representatives, providing oversight and strategic guidance aligned with long-term value creation in precision oncology.